Myriad Genetics (MYGN) EPS (Basic) (2016 - 2025)
Myriad Genetics (MYGN) has disclosed EPS (Basic) for 17 consecutive years, with -$0.07 as the latest value for Q4 2025.
- Quarterly EPS (Basic) rose 85.11% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.93 through Dec 2025, down 178.72% year-over-year, with the annual reading at -$3.95 for FY2025, 180.14% down from the prior year.
- EPS (Basic) for Q4 2025 was -$0.07 at Myriad Genetics, up from -$0.29 in the prior quarter.
- The five-year high for EPS (Basic) was $0.31 in Q3 2021, with the low at -$3.57 in Q2 2025.
- Average EPS (Basic) over 5 years is -$0.51, with a median of -$0.32 recorded in 2023.
- The sharpest move saw EPS (Basic) surged 255.0% in 2021, then plummeted 770.73% in 2025.
- Over 5 years, EPS (Basic) stood at -$0.1 in 2021, then tumbled by 420.0% to -$0.52 in 2022, then surged by 34.62% to -$0.34 in 2023, then plummeted by 38.24% to -$0.47 in 2024, then surged by 85.11% to -$0.07 in 2025.
- According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.07, -$0.29, and -$3.57 for Q4 2025, Q3 2025, and Q2 2025 respectively.